How to Tell If Your Low Blood Pressure Is Dangerously Low? All On Living With Hypotension
Low blood pressure, also known as hypotension, is usually considered a sign of good health and low risk for cardiovascular disease. However, there are times when persistently low blood pressure or a sudden drop can be a sign of an underlying health issue that needs medical attention. Knowing when low blood pressure becomes a problem can help ensure timely intervention and proper care.
Systolic pressure (the top number) indicates the pressure in your arteries when your heart pumps blood. Diastolic pressure (the bottom number) reflects the pressure in your arteries while your heart is resting between beats.
The normal reading is usually 120/80 mmHg or less. Hypotension is clinically defined as having blood pressure readings less than 90/60 mmHg. In some patients, low blood pressure will have no adverse health consequences and therefore does not need to be treated. In extreme cases, however, it can limit the flow of oxygen and nutrients to vital organs, resulting in potentially life-threatening complications, such as shock.
Hypotension can result from many factors. Some of the factors that cause hypotension are as follows:
While low blood pressure may not always cause symptoms, it can sometimes be associated with:
- Dizziness or fainting
- Fatigue and weakness
- Blurred vision
- Nausea
- Confusion or difficulty concentrating
- Shallow breathing
- Palpitations
If the person experiences these symptoms, with the recorded blood pressure reading, the medical services have to be consulted.
1. Orthostatic Hypotension: This is a kind of hypotension that appears as a result of decreased blood pressure when a person is standing up from lying down or sitting position and primarily affects elderly people.
2. Postprandial Hypotension: This is a drop in blood pressure after eating, more common in older people.
3. Neurally Mediated Hypotension: It is triggered by standing for long periods. This type can affect younger people and is associated with miscommunication between the brain and heart.
There is no such thing as a universal threshold for very low blood pressure, but a blood pressure reading below 90/60 mmHg can be dangerous and require prompt medical assessment if accompanied by symptoms of fainting, confusion, or shortness of breath. Sudden falls in blood pressure may point to potentially serious underlying causes, which can include:
Treatment of hypotension depends on its cause:
For more severe cases, physicians might also administer fludrocortisone or midodrine to increase blood pressure. Shock from hypotension should be treated promptly to ensure proper function of organs.
Chronic fatigue syndrome has also been associated with low blood pressure. Prolonged tiredness, despite adequate rest, may require reassessment of blood pressure levels. Fatigue secondary to hypotension will impact functionality and thus requires assessment and treatment of the cause.
If your blood pressure readings are low consistently and without symptoms, you probably have nothing to worry about. If you do have symptoms like dizziness, fainting, or confusion, you need to go to the doctor. Blood pressure checks are usually conducted regularly. Once you are aware of your own normal baseline, you will know right away when there is something wrong.
Credit: iStock
When patients first hear the term "bone marrow transplant," they often picture a complex surgery involving the bones or spine. This is perhaps the most persistent misconception surrounding one of modern medicine's most remarkable achievements.
Unlike other organ transplants (kidney/ heart/ liver, etc), a bone marrow transplant is not a surgery at all! It is administered much like a blood transfusion, through a simple intravenous line. Yet this deceptively simple procedure can rebuild an entire blood-forming and immune system from scratch, offering a genuine cure for blood cancers and other serious blood disorders.
Bone marrow is the body's blood factory, producing the red cells that carry oxygen, the white cells that fight infection, and the platelets that prevent bleeding. At its heart lie blood-forming stem cells or the "parent cells" capable of generating every blood cell the body will ever need.
In leukemia and related cancers, these stem cells turn rogue, crowding out healthy ones. In several inherited disorders, the marrow simply fails to manufacture healthy cells at all. A transplant addresses the problem at its root, replacing defective stem cells with healthy ones.
I often explain this to patients using the language of farming. Before sowing fresh seed, a farmer clears the field of weeds. Similarly, before healthy stem cells can be transplanted, doctors must prepare the marrow through chemotherapy and, in select cases, radiation, a stage called conditioning. Once this was punishingly intensive, limiting transplants to the young and fit. Today, reduced-intensity regimens, which are carefully tailored to suit even the old or frail patients, have extended this option to older adults and those with other health conditions.
The transplant itself is almost anticlimactic in its simplicity: stem cells are infused through an IV, with no incision or operating theatre required. These cells possess a natural ability doctors call "homing": they find their own way into the bone marrow and settle there. Over two to four weeks, they begin producing healthy blood, a process called engraftment.
For decades, the greatest obstacle to transplantation was finding a matched donor. Traditionally, only a fully matched sibling would do, leaving many patients, particularly in a genetically diverse country like India, without options. That has changed decisively. Half-matched family transplants and unrelated donors identified through registries now succeed at rates that rival matched-sibling transplants. Nearly every patient today has a realistic path to a suitable donor.
Technology is reshaping this field further. Gene therapy is opening a new chapter for disorders such as sickle cell disease and thalassemia, correcting a patient's own stem cells in the laboratory rather than relying on a donor, though such therapies remain costly and available only in select countries for now.
Recovery, however, is a marathon, not a sprint. It can take months as the immune system rebuilds, requiring vigilant monitoring for infection and for graft-versus-host disease, in which transplanted immune cells attack the patient's own tissues. Advances in immunosuppressive and targeted therapies have greatly improved our ability to manage this complication, allowing most survivors to gradually return to work, education and family life.
A blood cancer diagnosis remains frightening, but treatment has advanced tremendously in two decades. Bone marrow transplantation is no longer experimental or exceptionally hazardous: it is established, evidence-based, and growing safer and more accessible across India.
Its truest achievement is not simply extending life, but restoring it: another birthday, another child watched growing up, another future reclaimed. For these patients, a transplant is quite literally a chance to begin again.
(Dr. Narendra Agrawal, Hematologist and Bone Marrow Transplant Physician and Senior Consultant and Unit Head of Haemato-Oncology at Rajiv Gandhi Cancer Institute & Research Centre.)
Credit: iStock
A six-in-one (hexavalent) vaccine could make India's Universal Immunization Program more efficient, convenient for families, and cost-effective if it becomes widely available at an affordable price, according to a study led by the Ministry of Health and Family Welfare.
The study found that while the hexavalent vaccine has higher upfront procurement costs, it could reduce the number of injections, improve operational efficiency, lower healthcare workload, and save time for caregivers.
The hexavalent vaccine protects children against six diseases with a single injection:
Combining multiple vaccines into one shot reduces the number of injections infants receive during routine immunization visits.
Also read: India Records 20,138 Organ Transplants In 2025; Deceased Donor Transplants Reach 3,526
Researchers found that the vaccine's price is the biggest factor determining the overall cost of introducing it into India's immunization program.
The study estimated that:
The findings were published in the peer-reviewed journal Human Vaccines & Immunotherapeutics.
According to the study, introducing the hexavalent vaccine could:
Read More: India's National Hepatitis Program Screens Over 210.6 Million, Treats 612,000 Patients
India runs one of the world's largest immunization programs, vaccinating nearly 26 million babies every year.
The program protects children against 12 vaccine-preventable diseases, including:
A team of researchers, including from The George Institute for Global Health India, The Gates Foundation, and Gavi, The Vaccine Alliance, assessed two implementation scenarios:
The analysis considered costs from both government and household perspectives, including:
The researchers noted that replacing the current pentavalent, fIPV and DTP booster vaccines with the hexavalent vaccine would initially increase vaccine procurement costs. However, these would be partially offset by savings from:
The team added that based on previous vaccine procurement trends, a 50% reduction in the hexavalent vaccine price would make the switch economically favorable under the primary immunization schedule. Further price reductions could also generate cost savings for the booster-dose scenario.
"Our study demonstrates that although the hexavalent vaccine carries a higher upfront procurement cost, it also generates important efficiencies by reducing injections, easing pressure on frontline health workers, lowering cold-chain requirements and saving caregivers' time. These findings provide important economic evidence that can inform future policy discussions on strengthening India's immunization program," Dr. Susmita said.
Blockbuster GLP-1 drugs, with semaglutide as the key ingredient, have shown promise in treating conditions ranging from diabetes and obesity to certain cancers.
Now, US researchers are set to test whether semaglutide can also help treat alcohol use disorder (AUD), particularly among veterans. AUD affects an estimated 400 million people worldwide, or about 7% of people aged 15 years and older.
The US Department of Veterans Affairs (VA) has announced a new clinical trial to evaluate the effectiveness of semaglutide in treating AUD and is aimed directly at benefiting Veterans.
"By exploring emerging treatment options like the use of a GLP-1 for AUD, we aim to expand the tools available to help Veterans take control of their health and recovery," said VA Secretary Doug Collins.
Currently, more than 400,000 US veterans have been diagnosed with AUD, while an estimated 11% of US adults are affected by the condition.
Also read: GLP-1 Weight-Loss Drugs Show Promise for 17 Million With Binge Eating Disorder, Suggests Study
The study, called the Cessation or Reduction of Alcohol Consumption in Veterans (CRACV) trial, will enroll more than 600 veterans across 18 VA medical centers in the US.
Participants aged 18 to 80 with moderate or severe AUD will receive weekly injections of either semaglutide or a placebo for 24 weeks, followed by a safety follow-up period.
Researchers will assess changes in alcohol consumption, overall health, and quality of life to determine whether semaglutide could become a new treatment option for alcohol use disorder.
Evidence is also emerging that GLP-1 medications may influence alcohol consumption. A Phase 2 clinical trial published in the American Journal of Psychiatry in July suggests that oral semaglutide may help reduce heavy and harmful drinking, even among people who are not trying to quit alcohol completely.
The trial included 50 adults with moderate to severe alcohol use disorder who wanted to reduce or stop drinking. Participants were randomly assigned to receive either daily oral semaglutide or a placebo for eight weeks.
The semaglutide dose increased from 3 mg per day during the first four weeks to 7 mg per day during the remaining four weeks.
While semaglutide did not significantly reduce laboratory-assessed craving or the average number of drinks per day compared with placebo, it significantly reduced heavy drinking days.
Compared with participants receiving placebo, those taking semaglutide had fewer heavy drinking days during the final four weeks of treatment. They also consumed fewer drinks on drinking days and reported greater reductions in everyday alcohol cravings and alcohol-related negative consequences.
"It could represent a new treatment option for alcohol use disorder, particularly for those who have not benefited from existing medications, and may reduce alcohol-related health and social harms. Importantly, even reducing heavy drinking can lead to meaningful improvements for patients and families," said Joseph Schacht, PhD, professor of psychiatry at the University of Colorado Anschutz School of Medicine.
© 2024 Bennett, Coleman & Company Limited